Tandem Autologous Stem Cell Transplantation for Patients with Primary Refractory or Poor Risk Recurrent Hodgkin Lymphoma

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 5, 2007, Pages 594-600

  Fung, Henry C ^a   Stiff, Patrick ^a   Schriber, Jeff ^a   Toor, Amir ^a   Smith, Eileen ^a   Rodriguez, Tulio ^a   Krishnan, Amrita ^a   Molina, Arturo ^a   Smith, David ^a   Ivers, Barbara ^a   Kogut, Neil ^a   Popplewell, Leslie ^a   Rodriguez, Roberto ^a   Somlo, George ^a   Forman, Stephen J ^a   Nademanee, Auayporn ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Hodgkin lymphoma; Tandem transplant

Indexed keywords

BLEOMYCIN; CARMUSTINE; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ANEURYSM RUPTURE; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DRUG FATALITY; DRUG MEGADOSE; ENDOMETRIUM CARCINOMA; FEMALE; FOLLOW UP; HEALTH PROGRAM; HIGH RISK POPULATION; HODGKIN DISEASE; HUMAN; IMMUNOLOGICAL TOLERANCE; LIVER CARCINOMA; MALE; METASTASIS; MONOTHERAPY; MYELODYSPLASIA; OVERALL SURVIVAL; PILOT STUDY; PROGNOSIS; RADIATION DOSE; RECURRENT CANCER; SEPSIS; SOLID TUMOR; THERAPY EFFECT; VEIN OCCLUSION; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PILOT PROJECTS; PROGNOSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; WHOLE-BODY IRRADIATION;

EID: 34247152478     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2007.01.072     Document Type: Article

References (17)

1. Aisenberg A.C. Problems in Hodgkin's disease management. Blood 93 (1999) 761-779
2. Bonfante V., Santoro A., Viviani S., et al. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. [see comments]. J Clin Oncol. 15 (1997) 528-534
3. Longo D.L., Duffey P.L., Young R.C., et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol. 10 (1992) 210-218
4. Reece D.E., Connors J.M., Spinelli J.J., et al. Intensive therapy with cyclophosphamide, carmustine, etoposide ± cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. [see comments]. Blood 83 (1994) 1193-1199
5. Nademanee A., O'Donnell M.R., Snyder D.S., et al. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors. Blood 85 (1995) 1381-1390
6. Horning S.J., Chao N.J., Negrin R.S., et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 89 (1997) 801-813
7. Stiff P.J., Unger J., Fisher R.I., et al. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Sothwest Oncology Group Phase II trial. Biol Blood Marrow Transplant. 9 (2003) 529-539
8. Jones R.J., Paintadosi S., Mann R.B., et al. High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol. 8 (1990) 527-537
9. Lazarus H.M., Loberiza Jr. F.R., Zhang M.J., et al. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from autologous blood and marrow transplant registry. Bone Marrow Transplant. 27 (2001) 387-396
10. Wheeler C., Antin J.H., Churchill W.H., et al. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. J Clin Oncol. 8 (1990) 648-656
11. Reece D.E., Nevill T.J., Sayegh A., et al. Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's disease. Bone Marrow Transplant. 23 (1999) 1131-1138
12. Russell J.A., Selby P.J., Ruether B.A., et al. Treatment of advanced Hodgkin's disease with high dose melphalan and autologous bone marrow transplantation. Bone Marrow Transplant. 4 (1989) 425-429
13. Ahmed T., Lake D.E., Beer M., et al. Single and double autotransplants for relapsing/refractory Hodgkin's disease: results of two consecutive trials. Bone Marrow Transplant. 19 (1997) 449-454
14. Brice P., Divine M., simon D., et al., SFGM/GELA Study Group. Feasibility of tandem autologous stem-cell transplantation in induction failure or very unfavorable relapse from Hodgkin disease. Ann Oncol. 10 (1999) 1485-1488
15. Brice P., Bouabdallah R., Stamatoullas A., et al. Single or tandem autologous stem cell trasnplantation according to prognostic factors at first Hodgkin lymphoma progression/relapse. Leuk Lymphoma 42 suppl 2 (2001) 72
16. Tarella C., Cuttica A., Vitolo, et al. High dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence. Cancer 97 (2003) 2748-2759
17. Josting A., Rudolph C., Mapara M., et al. Cologone high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin lymphoma study Group. Ann Oncol. 16 (2005) 116-123